1 / 10

Global Self-Injectable Belimumab Market Outlook 2024: Global Opportunity & Growth Analysis, 2016-2024

The Self-injectable Belimumab Market size is set to reach USD 7.2 million by 2024, at a CAGR of 8.7% over the forecast years.

SteveBlade
Download Presentation

Global Self-Injectable Belimumab Market Outlook 2024: Global Opportunity & Growth Analysis, 2016-2024

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Global Self-InjectableBelimumabMarket Outlook 2024: Global Opportunity & Growth Analysis, 2016-2024 Report Code : HC1004 99 Wall Street, Suite No:- 527, New York, NY 10005 United States of America +1-646-568-7747 +1-437-886-1181 Office No:- 504, 5th Floor, C-51, BSI Business Park, Sector-62, Noida, PIN:- 201301 India  +44-203-318-6627 +91-120-473-0422, +91-844-785-9968 www.goldsteinresearch.com sales@goldsteinresearch.com

  2. Global Self-InjectableBelimumabMarket Outlook 2024: Global Opportunity & Growth Analysis, 2016-2024 Self-injectableBelimumabMarket The European Commission has rubber-stamped a brand new subcutaneous formulation of belimumab (Benlysta, GlaxoSmithKline) as adjunctive treatment for adults with active, autoantibody-positive systemic lupus erythematosus (SLE) with a high degree of disease activity despite standard therapy. Systemic lupus erythematosus (SLE), a heterogeneous condition that significantly impact on morbidity and mortality among affected individuals, mainly young females during their most productive stage in life. The production of pathogenic autoantibodies has been the classical hallmark for the disease. B cells, the precursor of the antibody producing plasma cells, are believed to play a central role in SLE disease activity. It has long been considered a difficult disease to manage and diagnose due to its wide raging manifestations and severity. Goldstein Research analyst forecast the Self-injectableBelimumab Market size is set to reach USD 7.2 million by 2024, at a CAGR of 8.7% over the forecast years.

  3. Global Self-InjectableBelimumabMarket Outlook 2024: Global Opportunity & Growth Analysis, 2016-2024 • Market Segmentation • By Mode of Injection • Subcutaneous Autoinjector • Subcutaneous Prefilled Syringe • Intravenous Infusion • Based on Geography • North America (U.S. & Canada) Self-injectableBelimumab Market • Latin America (Brazil, Mexico, Argentina & Rest of Latin America) Self-injectableBelimumab Market • Europe (The U.K., Germany, France, Italy, Spain, Poland, Sweden & RoE) Self-injectableBelimumab Market • Asia-Pacific (China, India, Japan, Singapore, South Korea, Australia, New Zealand, Rest of Asia) Self-injectableBelimumab Market • Middle East & Africa (GCC, South Africa, North Africa, RoMEA) Self-injectableBelimumab Market Sample Request

  4. Global Self-InjectableBelimumabMarket Outlook 2024: Global Opportunity & Growth Analysis, 2016-2024 • Based on Geography • North America Interactive Robots Market(U.S. & Canada) {Market Share (%), Market Size (USD Billion)} • Latin America Interactive Robots Market (Brazil, Mexico, Argentina & Rest of Latin America)  {Market Share (%), Market Size (USD Billion)} • Europe Interactive Robots Market (The U.K., Germany, France, Italy, Hungary, Spain, Poland, Sweden & RoE)  {Market Share (%), Market Size (USD Billion)} • Asia-Pacific Interactive Robots Market (China, India, Japan, Singapore, South Korea, Australia, New Zealand, Rest of Asia)  {Market Share (%), Market Size (USD Billion)} • Middle East & Africa Interactive Robots Market (GCC, South Africa, North Africa, RoMEA)  {Market Share (%), Market Size (USD Billion)} • Send us Sample Request @ https://www.goldsteinresearch.com/request-sample/global-self-injectable-belimumab-market-outlook-2016-2024 Sample Request

  5. Global Self-InjectableBelimumabMarket Outlook 2024: Global Opportunity & Growth Analysis, 2016-2024 Market Size and Forecast (2016-2024) The Self-injectableBelimumab Market size is set to reach USD 7.2 million by 2024, at a CAGR of 8.7% over the forecast years. Based on geography, GSK receives FDA approval for a new self-injectable formulation of Benlysta (belimumab) for systemic lupus erythematosus in Europe and US recently; therefore Europe tends to be the dominating market in global self-injectablebelimumab market in 2017. However, estimated incidence rates are 1 to 25 per 100,000 in North America, South America, Europe, and Asia and disease appears to be more common in urban than rural areas. In the United States, the prevalence of SLE is higher among Asians, African Americans, African Caribbean, and Hispanic Americans compared with Caucasians while in European countries, the prevalence of SLE is also higher among people of Asian and African descent hence, by comparison SLE occurs infrequently in Africa. In New Zealand, the prevalence and mortality of SLE are higher in Polynesians than Caucasians.

  6. Global Self-InjectableBelimumabMarket Outlook 2024: Global Opportunity & Growth Analysis, 2016-2024 • Scope Background • Market Synopsis • Self-injectableBelimumabMarket Segmentation • The Self-injectableBelimumabindustry is segmented as follows: • By Mode of Injcetion(Market Size, Demand Analysis and Growth Analysis) • By Geography(Market Size, Demand Analysis and Growth Analysis) • By Country • North America (U.S., Canada) {Market Size, Growth Analysis and Opportunity Analysis} • Latin America (Argentina, Mexico, Brazil and Rest of Latin America) {Market Size, Growth Analysis and Opportunity Analysis} • Europe (Germany, Italy, Spain, France, The U.K., Netherlands, Sweden, Hungary, Russia, Poland, Rest of Europe) {Market Size, Growth Analysis and Opportunity Analysis} • Asia-Pacific (China, India, Singapore, Japan, Australia, New Zealand, South Korea and Rest of Asia Pacific) {Market Size, Growth Analysis and Opportunity Analysis} • Middle East and North Africa (MENA) {Market Size, Growth Analysis and Opportunity Analysis} • Rest of World  {Market Size, Growth Analysis and Opportunity Analysis} Sample Request

  7. Global Self-InjectableBelimumabMarket Outlook 2024: Global Opportunity & Growth Analysis, 2016-2024 • Market Dynamics: Growth Drivers, Restraints and Opportunities • Risk Factors • Regional Variations • Recent Trends and Developments • Key Market Players • Synopsis • Business Strategy • Product Portfolio • SWOT Analysis • Porter’s Five Force Model • Market Landscape: Competition and Beyond • Market outlook for business players and entry level players to ascertain their business in dynamic ecosystem • Expert Analysis • Concluding Remarks • Request for TOC @ https://www.goldsteinresearch.com/toc-request/global-self-injectable-belimumab-market-outlook-2016-2024 Sample Request

  8. Global Self-InjectableBelimumabMarket Outlook 2024: Global Opportunity & Growth Analysis, 2016-2024 About Goldstein Research Based in U.S., Goldstein Research is a young business consulting company and market research firmwith vast reach across America, Asia and parts of Europe and the Middle East. In the next five years, we strive to expand our reach to 50+ nations spanning across Europe, Asia and parts of the Middle East and Africa. We strive to realize a strong brand presence globally through our quality research and forecasting solutions. With 30+ domain experts and 50+ employees working day and night to crunch numbers and bring out the best and detailed market reports and forecasts, we strive to enable you to foresee upcoming market challenges and develop a robust business model and strategies, which would add to your profitability and market visibility as a brand. Our mission is simple: to develop insightful business solutions, help our clients make powerful future decisions to keep them well ahead of the game which is the market, and leave a mark across businesses and communities through our well-defined ideas and clear cut forecasts. Our mission is simple: to develop insightful business solutions, help our clients make powerful future decisions to keep them well ahead of the game which is the market, and leave a mark across businesses and communities through our well-defined ideas and clear cut forecasts.

  9. Global Self-InjectableBelimumabMarket Outlook 2024: Global Opportunity & Growth Analysis, 2016-2024 Sample Request For more information Contact Us: 99 Wall Street, Suite No:- 527, New York, NY 10005 United States of America +1-646-568-7747 +1-437-886-1181 Office No:- 504, 5th Floor, C-51, BSI Business Park, Sector-62, Noida, PIN:- 201301 India  +44-203-318-6627 +91-120-473-0422, +91-844-785-9968 www.goldsteinresearch.com sales@goldsteinresearch.com

  10. Global Self-InjectableBelimumabMarket Outlook 2024: Global Opportunity & Growth Analysis, 2016-2024 Thank you Thank you

More Related